Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 12/20 | 0.39 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.36 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.36 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6388651 | 0.89 | AKR1C3 (0.42) | AKR1C3AKR1C2NR1H2TUBB1NR1H3 | |
| SCHEMBL5839140 | 0.89 | AKR1C3 (0.42) | AKR1C3AKR1C2NR1H2TUBB1NR1H3 | |
| SCHEMBL10173695 | 0.84 | NR1H2 (0.49) | AKR1C3AKR1C2NR1H2TUBB1NR1H3 | |
| SCHEMBL18966700 | 0.83 | ESR2 (0.43) | AKR1C3AKR1C2NR1H2TUBB1NR1H3 | |
| SCHEMBL12717579 | 0.83 | NR1H2 (0.37) | CYP2A6NR1H2GPR119NR1H3CA12 | |
| SCHEMBL13291504 | 0.82 | KMT2A (0.53) | — | |
| Acetic Acid SCHEMBL8646221 | 0.82 | NR1H2 (0.41) | AKR1C3AKR1C2NR1H2NR1H3 | |
| SCHEMBL4389624 | 0.82 | AKR1C3 (0.49) | AKR1C3AKR1C2NR1H2NR1H3 | |
| SCHEMBL1621434 | 0.82 | NR1H2 (0.43) | NR1H2TUBB1NR1H3 | |
| SCHEMBL5436506 | 0.82 | NR1H2 (0.44) | AKR1C3AKR1C2NR1H2TUBB1NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928231-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-19 | — | — | US | disclosed |
| EP-1682553-B1 | THIENOPYRAZOLES | AVENTIS PHARMA INC (US) | 2010-05-19 | — | — | EP | disclosed |
| US-20100056514-A1 | THIENOPYRAZOLES | AVENTIS PHARMACEUTICALS INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-7518000-B2 | Thienopyrazoles | AVENTIS PHARMACEUTICALS, INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20070254937-A1 | Thienopyrazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056514-A1 | THIENOPYRAZOLES | ITK, IL2, TYK2 | AKR1C3 3715/4885AKR1C2 3385/4885CYP2A6 1989/4885 |
| US-20070254937-A1 | Thienopyrazoles | ITK, IL2, JAK2 | AKR1C3 2833/4885AKR1C2 2565/4885CYP2A6 1343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.